Q32 Bio Q3 2026 earnings

QTTB · 2026-11-04 07:03 BMO ET · 8-K on SEC · 10-Q on SEC

Net loss narrowed to $8.9 million, or $0.26 per share, driven by higher operating expenses and other income offset by a lower share count.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $10.7 million (+40.8% YoY)
  • One-offs in the quarter Loss on extinguishment of debt $147k; Other income $1.7 million
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$289.6 million$106.3 million$48.3 million+172.3% QoQ
Weighted-average common shares34.0 million20.3 million12.2 million+67.5% QoQ

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story EPS improvement driven by a 67.5% increase in weighted-average shares and a 56.7% reduction in net loss per share.
  • One-off check Other income increased to $1.7 million from $188 thousand YoY, and a loss on extinguishment of debt of $147 thousand was recorded.

The good

  • Cash and cash equivalents increased to $289.6 million as of September 30, 2026

The bad

  • Research and development expenses increased 44.6% YoY to $5.1 million
  • General and administrative expenses increased 37.1% YoY to $5.5 million

The ugly

  • none

Open questions

  • What caused the significant increase in other income?
  • What specific regulatory discussions are planned for the fourth quarter of 2026?
Full release

Q32 Bio (QTTB) earnings release, November 4, 2026

Q32 Bio Inc. (QTTB) · Form 8-K, Item 2.02 · Filed · SEC filing

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of bempikibart as a chronic treatment in AA --

-- Robust durability, including maintenance and deepening of response, observed through the 16-week off-drug period in Part B supporting potential for less frequent, chronic maintenance dosing --

-- SIGNAL-AA Part B open-label extension (OLE) ongoing; data expected in 2H’2027 --

-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H’2027 subject to planned regulatory discussions this quarter --

-- Strengthened leadership team including appointments of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer --

-- Cash and cash equivalents of $289.6 million as of September 30, 2026 expected to provide financial runway through Phase 3 topline results from planned registration-directed program --

WALTHAM, Mass.— November 4, 2026 – Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (“AA”) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate updates.

“The third quarter brought continued momentum for Q32 Bio and our bempikibart program. We shared encouraging SIGNAL-AA Part B results in late-breaking oral and poster presentations at EADV, highlighting bempikibart’s clinically meaningful efficacy data at Week 36 and ability to induce durable responses that were maintained or deepened through the 16-week off-drug period, supporting the potential for less frequent, chronic maintenance dosing,” said Jodie Morrison, Chief Executive Officer of Q32 Bio. “We believe our data demonstrates the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata. We are pleased to welcome José and Ellie to lead the advancement of bempikibart into late-stage development and have made key senior appointments spanning clinical operations, clinical strategy and medical affairs, and regulatory affairs. With a strong balance sheet, we believe we are well positioned to rapidly advance into a registration-directed program in severe or very severe alopecia areata in the first half of 2027 following planned regulatory discussions this quarter, as well as in other autoimmune and inflammatory indications.”

Third Quarter 2026 and Recent Business Highlights

• Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial at EADV Congress 2026.

In September 2026, Q32 Bio presented results from Part B of the SIGNAL-AA Phase 2a clinical trial in a late-breaking oral presentation and a poster presentation at the European Academy of Dermatology and Venereology (“EADV”)

Congress 2026 in Vienna, Austria. Part B is an open-label clinical trial evaluating bempikibart, a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, in 33 patients with severe or very severe AA. Patients are treated with bempikibart for 36 weeks followed by a 16-week off-drug follow-up period before optional enrollment in the open-label extension ("OLE"). In Part B at Week 36, bempikibart demonstrated clinically meaningful efficacy data on the primary endpoint with a mean percent reduction in Severity of Alopecia Tool ("SALT") score from baseline of 35.3% in the prespecified modified intent-to-treat ("mITT") analysis. Additionally, 40.0% of patients achieved a SALT-20 (80% of scalp hair coverage) response at Week 36 in the mITT analysis and 30.3% of patients achieved a SALT-20 response at Week 36 in the intent-to-treat ("ITT") analysis of all enrolled patients. In the 16-week off-drug follow-up period, bempikibart demonstrated robust durability, including maintenance and deepening of response, supportive of less frequent, chronic maintenance dosing after an initial treatment period. Biomarker results and biopsy findings supported bempikibart’s mechanism of action, and bempikibart was generally well-tolerated, consistent with prior studies, with no new safety signals. Q32 Bio previously announced topline results from Part B of SIGNAL-AA in July 2026.

• SIGNAL-AA Part B OLE remains ongoing.

Following completion of the Part B 36-week treatment period and 16-week off-drug follow-up period, eligible patients enrolled in the Part B OLE. Dosing remains ongoing in the OLE. Analysis from the Part B 16-week off-drug follow-up period and OLE will help inform long-term chronic maintenance regimens, which could include monthly, bi-monthly or quarterly dosing, which will be evaluated in future studies. Q32 Bio anticipates data from the Part B OLE in the second half of 2027.

• Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in the first half of 2027 and additional development opportunities being evaluated.

Q32 Bio plans to advance bempikibart into a registration-directed program for patients with severe or very severe AA in the first half of 2027 subject to planned regulatory discussions in the fourth quarter of 2026. Additionally, based on clinical results as well as changes on biomarkers supportive of bempikibart’s bifunctional mechanism, Q32 Bio is evaluating opportunities for bempikibart in expanded AA populations as well as in additional immunology and inflammation (“I&I”) indications.

• ... (truncated)al operations, clinical strategy and medical affairs and regulatory affairs.

In September 2026, Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development. Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory strategy. In addition to the appointments of Dr. Trevejo and Dr. Hershberger, Q32 Bio has continued to build out its team with key clinical operations, clinical strategy and medical affairs and regulatory affairs appointments.

• Half-life extended fully human anti-IL-7Rα program, ADX-914-XL, continues in preclinical development.

Developed using half-life extension technology, ADX-914-XL is designed to provide the clinical activity and safety profile observed to date with bempikibart while offering an extended dosing schedule.

• Completed $200.0 million public offering.

In July 2026, Q32 Bio completed a public offering of common stock and pre-funded warrants, raising gross proceeds of approximately $200.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Q32 Bio.

Financial Results

• Cash and cash equivalents were $289.6 million as of September 30, 2026. Q32 Bio believes its cash and cash equivalents as of September 30, 2026 are sufficient to fund operations through topline Phase 3 results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe AA.

• Research and development expenses were $5.1 million for the three months ended September 30, 2026, compared to $3.6 million for the three months ended September 30, 2025. The increase was primarily due to higher bempikibart clinical and manufacturing costs as compared to the prior year, as well as preclinical development costs for ADX-914-XL.

• General and administrative expenses were $5.5 million for the three months ended September 30, 2026, compared to $4.0 million for the three months ended September 30, 2025. The increase was primarily due to higher stock-based compensation expense and other employee-related costs as compared to the prior year.

• Net loss was $8.9 million, or $0.26 basic and diluted net loss per share, for the three months ended September 30, 2026, compared $7.4 million, or $0.60 basic and diluted net loss per share, for the three months ended September 30, 2025.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.¹

National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Financial statements

Income Statement

Q32 BIO INC. — david.rosen@argotpartners.com (in thousands, except share and per share amounts)

Q32 BIO INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended September 30, – 2026Q32 BIO INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Three Months Ended September 30, – 2025Q32 BIO INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended September 30, – 2026Q32 BIO INC. – CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited) – Nine Months Ended September 30, – 2025
Operating expenses:
Research and development5,1493,55512,62615,841
General and administrative5,5114,02214,87413,136
Total operating expenses10,6607,57727,50028,977
Loss from operations-10,660-7,577-27,500-28,977
Loss on extinguishment of debt-147
Other income, net1,7381882,1701,068
Total other income1,7381882,0231,068
Net loss and comprehensive loss-8,922-7,389-25,477-27,909
Net loss per share—basic and diluted-0.26-0.6-1.11-2.29
Weighted-average common shares—basic and diluted34,022,75512,240,54222,912,87512,212,081

Balance Sheet

Q32 BIO INC. — david.rosen@argotpartners.com (in thousands)

Q32 BIO INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – September 30, 2026 – (Unaudited)Q32 BIO INC. – CONDENSED CONSOLIDATED BALANCE SHEETS – December 31, 2025
Assets
Cash and cash equivalents289,58748,297
Right-of-use asset, operating leases4,6015,100
Restricted cash and restricted cash equivalents647647
Other assets2,3667,732
Total assets297,20161,776
Liabilities and stockholders’ equity
Accounts payable, accrued expenses and other current liabilities5,1675,111
Lease liability, net of current portion4,3644,943
Venture debt9,708
Stockholders’ equity287,67042,014
Total liabilities and stockholders’ equity297,20161,776

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (UNAUDITED) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-25,477-27,909
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and issuance costs, net of accrued interest-34143
Depreciation expense259301
Stock-based compensation expense6,1333,786
Non-cash lease expense499464
Loss on extinguishment of venture debt147
Loss on impairment of equity investment74
Change in fair value of CVR liability-374
Changes in operating assets and liabilities:
Prepaid expenses and other current assets5,2142,141
Other noncurrent assets116
Accounts payable210-2,016
Operating lease liability-514-455
Accrued expenses and other current liabilities-273-3,634
Net cash used in operating activities-13,836-27,363
Cash flows from investing activities:
Purchases of property and equipment-52
Net cash used in investing activities-52
Cash flows from financing activities:
Principal payments on venture debt-3,125-1,563
Payoff of venture debt-6,696
Proceeds from issuance of common stock and pre-funded warrants in Follow-On Financing, net of issuance costs187,501
Proceeds from issuance of common stock and pre-funded warrants in Registered Direct Offering, net of issuance costs10,360
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs53,354
Proceeds from issuance of common stock pursuant to at-the-market offering, net of discounts and issuance costs13,494
Proceeds from option exercises290
Net cash provided by (used in) financing activities255,178-1,563
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents241,290-28,926
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period48,94478,612
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period290,23449,686

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, Q32 Bio's beliefs, observations, expectations and assumptions regarding the results from the Part B of the SIGNAL-AA Phase 2a clinical trial, the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart, plans and expectations for Part B of the SIGNAL-AA Phase 2a clinical trial, the anticipated timing of data results, safety, tolerability and findings from the potential Part B OLE, the potential of advancing bempikibart in other autoimmune and inflammatory conditions, the expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including bempikibart, and anticipated milestones, timing of anticipated registrational trials, data readouts and timing, the plans and timing of the preclinical development of ADX-914-XL, the United States AA market size and potential commercial opportunities, Q32 Bio’s expectations regarding the strength of its leadership team, and Q32 Bio's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, including statements regarding sufficiency of its cash and cash equivalents to provide financial runway through topline Phase 3 results from its planned registration-directed program evaluating bempikibart in patients with severe or very severe AA, among others, are forward-looking statements; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner than currently anticipated, Q32 Bio’s expectations regarding the sufficiency of its cash and cash equivalents to provide financial runway and that Q32 Bio may need additional funding to complete clinical studies, which may not be available on favorable terms or at all and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contacts

Investors: Brendan Burns

Senior Director, Investor Relations and Corporate Communications

Q32 Bio bburns@q32bio.com

Media: David Rosen

Argot Partners

646.461.6387 david.rosen@argotpartners.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Q32 Bio earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.